Seikagaku entered into an agreement with Eisai to co-develop and market SI-613 sodium hyaluronate in China to treat knee osteoarthritis.
Upon regulatory approval, Eisai will take on distribution. The companies will equally share development costs, and Eisai will pay Seikagaku an upfront payment, along with development and sales milestones.
SI-613 uses a proprietary drug-binding technology to chemically bond hyaluronic acid and diclofenac. The combination offers analgesic and anti-inflammatory effects with improved joint function.